Ce ("Charles") Li > Goodwin > Washington DC, United States > Lawyer Profile
Goodwin Offices

1900 N Street NW
Washington, District of Columbia 20036
United States
- Firm Profile
- Go to...
Ce ("Charles") Li

Position
Counsel
Career
Ce (“Charles”) Li is a counsel in the firm’s Global Trade and Intellectual Property practices. Dr. Li advises clients on U.S. export controls and sanctions compliance, and in connection with national security reviews of foreign investment in the United States. He has assisted clients in export classifications, license applications, compliance programs, internal investigations, voluntary disclosures, import law and customs regulations, and deal support (due diligence).
As a member of Goodwin’s IP practice, he helps clients protect patent and trade secret rights and defend against various IP infringement claims in federal courts and before the U.S. International Trade Commission. Dr. Li is experienced in post-grant proceedings (e.g., inter partes reviews or IPRs) and has rendered patentability, non-infringement, and invalidity opinions. Dr. Li also assists clients in IP rights counseling, licensing and procurement, including patent portfolio development and NPE strategies.
Education
JD 2006 Georgetown University Law Center (cum laude); Doctor of Philosophy Electrical & Computer Engineering 2003 Cornell University; MA Plasma Physics & Technology 1998 Princeton University; BS Modern Physics 1996 University of Science & Technology of China (magna cum laude)
Top Tier Firm Rankings
- Industry focus > Cannabis
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Dispute resolution > E-discovery
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Intellectual property > Patents: litigation (full coverage)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- M&A/corporate and commercial > Shareholder activism
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- International trade and national security > CFIUS
- Finance > Commercial lending
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade and national security > Customs, export controls and economic sanctions
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Intellectual property > Patents: litigation (International Trade Commission)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Healthcare > Service providers
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Real estate > Real estate finance
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Finance > Financial services regulation